Drugs / Partially HLA-matched SARS-CoVSTs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04401410 | Nov 2020 → Oct 2021 | COVID-19 | Baylor College of Medicine | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Partially HLA-matched SARS-CoVSTs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04401410 ↗ |
| Known as | ALVR109 | “The feasibility of making and safely utilizing such virus-specific T cells clinically was assessed by administering partially HLA-matched, third-party, cryopreserved...” PMID 36373249 ↗ Jul 2023 |
| Modality | Cell therapy | “cryopreserved SARS-CoV-2-specific T cells” PMID 36373249 ↗ Jul 2023 |
| Route | Intravenous | “The cells will be thawed and given through an intravenous line.” NCT04401410 ↗ |